

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jwoldike et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: November 13, 2001

Examiner: To be assigned

For: Method for the Production of FVII

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, after the Title, please insert:

--CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Serial No. 09/558,027 filed on April 25, 2000, which is a continuation of PCT/DK99/00607 filed on November 5, 1999, and claims priority under 35 U.S.C. 119 of U.S. provisional application no. 60/108,065 filed on November 12, 1998, Danish application no. PA 1998 01436 filed on November 6, 1998 and Danish application no. PA 1998 01439 filed on November 9, 1998, the contents of which are fully incorporated herein by reference.--

IN THE SEQUENCE LISTING:

Please delete the original Sequence Listing, and replace with the attached Sequence Listing.

REMARKS


Entry of this amendment is respectfully requested.

Applicants enclose herewith a Sequence Listing to be substituted for the Sequence Listing attached to the application as filed. In accordance with 37 CFR 1.821(e), please use the last computer readable form filed in U.S. Serial No. 09/558,027 as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. The content of the attached paper entitled "SEQUENCE LISTING" and of the diskette filed in the parent application is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed. No new matter is added.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: November 13, 2001


Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

